Suppr超能文献

乳腺癌患者接受选择性雌激素受体调节剂治疗后发生的子宫恶性混合性苗勒管肿瘤:13例报告及其临床病理特征

Uterine Malignant Mixed Müllerian Tumors Following Treatment with Selective Estrogen Receptor Modulators in Patients with Breast Cancer: A Report of 13 Cases and Their Clinicopathologic Characteristics.

作者信息

Jeong Byung-Kwan, Sung Chang O, Kim Kyu-Rae

机构信息

Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

出版信息

J Pathol Transl Med. 2019 Jan;53(1):31-39. doi: 10.4132/jptm.2018.11.16. Epub 2018 Dec 18.

Abstract

BACKGROUND

Breast cancer treatment with selective estrogen receptor modulators (SERMs) increasesthe incidence of uterine malignant mixed Müllerian tumors (uMMMTs). We examine clinicopathologiccharacteristics and prognosis of SERM-associated uMMMTs (S-uMMMTs) and discusspossible pathogenetic mechanisms.

METHODS

Among 28,104 patients with breast cancer, clinicopathologicfeatures and incidence of uMMMT were compared between patients who underwentSERM treatment and those who did not. Of 92 uMMMT cases that occurred during the same period,incidence, dose, and duration of SERM treatment, as well as overall survival rate, were comparedfor patients with breast cancer who underwent SERM treatment and those who did not (S-uMMMTvs NS-uMMMT) and for patients without breast cancer (de novo-uMMMT). Histopathologicalfindings and immunophenotypes for myogenin, desmin, p53, WT-1, estrogen receptor (ER) α, ERβ,progesterone receptor, and GATA-3 were compared between S-uMMMT and de novo-uMMMT.

RESULTS

The incidence of S-uMMMT was significantly higher than that of NS-uMMMT (6.35-fold).All patients with SERM were postmenopausal and received daily 20-40 mg SERM. CumulativeSERM dose ranged from 21.9 to 73.0 g (mean, 46.0) over 39-192 months (mean, 107). Clinicopathologicfeatures, such as International Federation of Gynecology and Obstetrics stage andoverall survival, were not significantly different between patients with S-uMMMT and NS-uMMMTor between patients with S-uMMMT and de novo-uMMMT. All 11 S-uMMMT cases available forimmunostaining exhibited strong overexpression/null expression of p53 protein and significantlyincreased ERβ expression in carcinomatous and sarcomatous components.

CONCLUSIONS

SERMtherapy seemingly increases risk of S-uMMMT development; however, clinicopathologic featureswere similar in all uMMMTs from different backgrounds. p53 mutation and increased ERβ expressionmight be involved in the etiology of S-uMMMT.

摘要

背景

使用选择性雌激素受体调节剂(SERM)治疗乳腺癌会增加子宫恶性混合苗勒管肿瘤(uMMMT)的发病率。我们研究了SERM相关的uMMMT(S-uMMMT)的临床病理特征和预后,并探讨了可能的发病机制。

方法

在28104例乳腺癌患者中,比较接受SERM治疗和未接受SERM治疗的患者的临床病理特征及uMMMT的发病率。在同期发生的92例uMMMT病例中,比较接受SERM治疗和未接受SERM治疗的乳腺癌患者(S-uMMMT与非S-uMMMT)以及无乳腺癌患者(新发uMMMT)的SERM治疗发病率、剂量和持续时间,以及总生存率。比较S-uMMMT与新发uMMMT之间的组织病理学结果以及生肌调节因子、结蛋白、p53、WT-1、雌激素受体(ER)α、ERβ、孕激素受体和GATA-3的免疫表型。

结果

S-uMMMT的发病率显著高于非S-uMMMT(6.35倍)。所有接受SERM治疗的患者均为绝经后女性,每日接受20 - 40 mg SERM治疗。在39 - 192个月(平均107个月)内,SERM累积剂量范围为21.9至73.0 g(平均46.0 g)。S-uMMMT患者与非S-uMMMT患者之间以及S-uMMMT患者与新发uMMMT患者之间的临床病理特征,如国际妇产科联盟分期和总生存率,无显著差异。所有11例可进行免疫染色的S-uMMMT病例均显示p53蛋白强过表达/无表达,且癌性和肉瘤性成分中ERβ表达显著增加。

结论

SERM治疗似乎会增加S-uMMMT发生的风险;然而,不同背景的所有uMMMT的临床病理特征相似。p53突变和ERβ表达增加可能参与了S-uMMMT的病因学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84c1/6344802/4e10e14ceaad/jptm-2018-11-16f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验